Abingworth is a transatlantic bioscience investment firm founded in 1973, dedicated to investing in life sciences and healthcare companies across the US and Europe. The firm provides capital and expertise from seed through development stage, including venture and clinical co-development strategies.
52% of their portfolio is in Biotech & Life Sciences. Deal activity increased 40% year-over-year (7 deals in the last 12 months). Average disclosed round size is $84.5M (across 96 rounds with reported amounts).
Portfolio
69
Fund Size
$465M
Top Stage
Series A
Last 12 Mo
7
Team
Kurt von Emster
Managing Partner
Andrew Sinclair
Managing Director, Head of Publics & Late Stage
Jayson Punwani
Managing Director, Head of Venture
Robert DeBenedetto
Managing Director, CCD
Travis Wilson
Managing Director, CCD
Carlos Paya
Venture Partner
Natalie Mount
Venture Partner
Scott Brun
Venture Partner
Tim Haines
Executive Partner
Vincent Miles
Executive Director
Diya Malhotra
Principal
Graham Mills
Principal
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Solve Therapeutics | Bridge | $120M | Sep 2026 |
 cAMPfield Therapeutics | Series A | $180M | Jun 2026 |
| CcAMPfield | Series A | $180M | Jun 2026 |
 Cytospire Therapeutics | Series A | — | May 2026 |
 R1 Therapeutics | Series A | $77.5M | Mar 2026 |
| Cytospire Therapeutics | Series A | $61M | Jan 2026 |
| CcAMPfield | Series A | $180M | Jan 2026 |
| Solve Therapeutics | Unknown | $120M | Jan 2026 |
| cAMPfield Therapeutics | Series A | $180M | Jan 2026 |
| R1 Therapeutics | Series A | $77.5M | Jan 2026 |
 Addition Therapeutics | Unknown | $100M | Dec 2025 |
| Solve Therapeutics | Series D | $120M | Nov 2025 |
 Wugen | Series B | $115M | Aug 2025 |
 Portola | Series A | — | Jul 2025 |
 Atsena Therapeutics | Series C | $150M | Apr 2025 |
| AAtsena | Series C | $150M | Apr 2025 |
 Reneo | Series B | $47.3M | Feb 2025 |
 Timberlyne Therapeutics | Series A | $180M | Jan 2025 |
 AdvanCell | Series C | $112M | Jan 2025 |
 Glycomine, Inc. | Series C | $115M | Jan 2025 |
| Atsena Therapeutics | Series C | $150M | Jan 2025 |
| Wugen | Series A | $115M | Jan 2025 |
 Iambic Therapeutics | Unknown | $50M | Jun 2024 |
| AAttralus | Series B | $201M | Feb 2024 |
| Iambic Therapeutics | Series B | $220M | Jan 2024 |
Top Co-Investors
Last updated: 20 October 2026